3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
4
Neoplasm Metastasis
2
Rheumatoid Arthritis, Systemic Juvenile
1
Periodic Fevers Syndrome
1
Mevalonate Kinase Deficiency
1
Metastatic Pancreatic Ductal Adenocarcinoma
1
Melanoma
1
Cryopyrin-Associated Periodic Syndromes
1
Carcinoma
1
Bronchiolitis Obliterans Syndrome
1
Arthritis, Juvenile
1
Arthralgia
1
Interventions
Gemcitabine
43
pembrolizumab
36
Paclitaxel
36
Nivolumab
31
Docetaxel
29
Capecitabine
29
Bevacizumab
29
Oxaliplatin
28
Fluorouracil
28
Cisplatin
26
Leucovorin
24
Cyclophosphamide
23
Radiosurgery
20
Irinotecan
20
Carboplatin
20
aldesleukin
19
Cetuximab
19
Interleukin-2
16
fludarabine phosphate
15
fludarabine
15
Pemetrexed
15
Trastuzumab
14
Magnetic Resonance Spectroscopy
14
Ipilimumab
14
Fulvestrant
14
130-nm albumin-bound paclitaxel
14
Prednisone
13
Everolimus
13
Radiotherapy
12
Panitumumab
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Neoplasm Metastasis
×
canakinumab
×
Clear all
NCT03631199
2026-02-25
CANOPY-1
Novartis
Phase 3
Terminated
673 enrolled
38 charts
NCT03626545
2023-08-21
CANOPY-2
Novartis
Phase 3
Terminated
245 enrolled
29 charts